Viking Says Monthly Dose Kept 90% of Weight Loss
Viking Therapeutics said on September 22, 2026 that people on monthly maintenance doses of its obesity drug VK2735 kept up to 90% of the average weight loss from the early treatment phase. Viking Therapeutics VK2735 is a GLP-1/GIP agonist, a drug that mimics two gut hormones to curb appetite. The study tested several maintenance schedules.
Viking had announced on January 8, 2026 that enrollment in this obesity maintenance trial was complete. Viking Therapeutics After Week 19, participants moved from induction, the first phase aimed at losing weight, to maintenance dosing given weekly, every other week, or monthly. Think sprint versus marathon: induction is the sprint down, maintenance is the long run to stay down.
The company had described induction results in its second-quarter 2026 update. Up to 80% of people on VK2735 lost at least 10% of body weight after 13 weeks, compared with 5% on placebo, an inactive treatment. Viking Therapeutics In a separate 13-week Phase 2 VENTURE trial of a once-daily pill, weight fell up to 12.2% from baseline. That result was statistically significant, meaning unlikely to be due to chance. Viking Therapeutics
On tolerability, a 2026 peer-reviewed study reported that all injected doses lowered weight and side effects were mainly gastrointestinal, like nausea. Viking has said all groups kept most of the loss four weeks after the final dose, and a February update said doses below 30 mg daily might hold weight steady.
Viking said on July 29, 2026 that the injected drug was in Phase 3 trials for obesity, the large late trials used for approval, including tests of maintenance dosing. Reuters reported on February 11, 2026 that Viking planned to move the pill version into a late-stage trial later that year. Reuters Investors have been strict. On August 19, 2025, Reuters and Bloomberg reported Viking shares fell after the 12.2% pill readout.
The broader context here is that maintenance is now the central test for this drug class, not early loss alone. How long people stay on treatment, how gut side effects feel over months, and how much drug is needed to hold results will shape production costs and what insurers will pay.
In my view, anyone valuing Viking should look past the headline word positive. A statistically significant 12.2% loss did not prevent a selloff last year. What counts now is kilograms kept in each dosing group, how steady the up-to-90% figure was, what happened after Week 19, and whether lower doses keep the side-effect pattern seen so far. Phase 3 choices on starting dose, who is re-randomized, and pill versus shot order will matter more than the topline label.
